Benjamin M Scirica

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Clinical application of C-reactive protein across the spectrum of acute coronary syndromes
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02461, USA
    Clin Chem 53:1800-7. 2007
  2. doi request reprint Association between natriuretic peptides and mortality among patients admitted with myocardial infarction: a report from the ACTION Registry(R)-GWTG™
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Clin Chem 59:1205-14. 2013
  3. doi request reprint The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Am Heart J 162:818-825.e6. 2011
  4. doi request reprint Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial
    Benjamin M Scirica
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Lancet 380:1317-24. 2012
  5. ncbi request reprint Ranolazine in patients with coronary artery disease
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Expert Opin Pharmacother 8:2149-57. 2007
  6. ncbi request reprint Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischem
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    Circulation 116:1647-52. 2007
  7. doi request reprint Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Clin Chem 55:265-73. 2009
  8. doi request reprint Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarcti
    Benjamin M Scirica
    TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 53:1411-21. 2009
  9. ncbi request reprint A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    Eur Heart J 28:2070-6. 2007
  10. doi request reprint The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiogr
    Benjamin M Scirica
    TIMI Study Group, Brigham and Women s Hospital, Cardiovascular Division, 350 Longwood Avenue, Boston, MA 02215, USA
    J Am Coll Cardiol 57:1908-16. 2011

Detail Information

Publications60

  1. ncbi request reprint Clinical application of C-reactive protein across the spectrum of acute coronary syndromes
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02461, USA
    Clin Chem 53:1800-7. 2007
    ..The ability to formulate recommendations regarding clinical use of hsCRP is limited by a paucity of data regarding several key issues. The purpose of this study was to evaluate hsCRP across the spectrum of ACS...
  2. doi request reprint Association between natriuretic peptides and mortality among patients admitted with myocardial infarction: a report from the ACTION Registry(R)-GWTG™
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Clin Chem 59:1205-14. 2013
    ..The objectives of this analysis were to evaluate the utilization and the prognostic value of NP in a large, real-world MI cohort...
  3. doi request reprint The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Am Heart J 162:818-825.e6. 2011
    ....
  4. doi request reprint Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial
    Benjamin M Scirica
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Lancet 380:1317-24. 2012
    ..We tested this effect in a subgroup of patients from the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial...
  5. ncbi request reprint Ranolazine in patients with coronary artery disease
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Expert Opin Pharmacother 8:2149-57. 2007
    ..Thus, ranolazine offers clinicians a new therapy in the long-term treatment of patients with chronic angina...
  6. ncbi request reprint Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischem
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    Circulation 116:1647-52. 2007
    ..Ranolazine reduces proarrhythmic substrate and triggers such as early afterdepolarization in experimental models. However, the potential antiarrhythmic actions of ranolazine have yet to be demonstrated in humans...
  7. doi request reprint Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Clin Chem 55:265-73. 2009
    ....
  8. doi request reprint Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarcti
    Benjamin M Scirica
    TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 53:1411-21. 2009
    ..The purpose of this study was to assess the relationship between ischemia detected on continuous electrocardiographic (cECG) recording and cardiovascular outcomes after acute coronary syndrome (ACS)...
  9. ncbi request reprint A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    Eur Heart J 28:2070-6. 2007
    ..To determine the relationship between a strategy of enoxaparin (ENOX), early ST-segment resolution (STRes), and clinical outcomes on patients with ST-segment elevation myocardial infarction (STEMI) after fibrinolysis...
  10. doi request reprint The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiogr
    Benjamin M Scirica
    TIMI Study Group, Brigham and Women s Hospital, Cardiovascular Division, 350 Longwood Avenue, Boston, MA 02215, USA
    J Am Coll Cardiol 57:1908-16. 2011
    ....
  11. doi request reprint Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 32:697-705. 2011
    ....
  12. doi request reprint Acute coronary syndrome: emerging tools for diagnosis and risk assessment
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 55:1403-15. 2010
    ..This review identifies promising new or emerging techniques, as well as established tools, and reviews their current or potential role in clinical practice...
  13. doi request reprint Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 31:1993-2005. 2010
    ....
  14. ncbi request reprint Ranolazine in patients with angina and coronary artery disease
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Curr Cardiol Rep 9:272-8. 2007
    ..Ranolazine complements traditional antianginal agents and offers clinicians a new option in the long-term treatment of patients with angina...
  15. doi request reprint Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thr
    Benjamin M Scirica
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, Mass 02115, USA
    Circulation 122:455-62. 2010
    ..The incidence and prognostic implications of VT in patients with non-ST-elevation acute coronary syndrome receiving contemporary care have not been examined...
  16. ncbi request reprint Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 47:2326-31. 2006
    ..We aimed to determine whether intensive statin therapy reduces hospitalization for heart failure (HF) in high-risk patients...
  17. ncbi request reprint The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 48:37-42. 2006
    ..This study was designed to determine the relationship between clopidogrel and early ST-segment resolution (STRes) and the interaction of the two with clinical outcomes after fibrinolysis...
  18. ncbi request reprint Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Thromb Thrombolysis 22:95-102. 2006
    ..To assess etiology and impact of thrombocytopenia in a large oral glycoprotein (GP) IIb/IIIa inhibitor trial...
  19. ncbi request reprint Treatment of elevated cholesterol
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 111:e360-3. 2005
  20. doi request reprint Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes
    Marc P Bonaca
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Coll Cardiol 60:332-8. 2012
    ..This study sought to investigate whether pregnancy-associated plasma protein-A (PAPP-A) is useful for risk assessment in non-ST-segment elevation acute coronary syndrome (NSTE-ACS)...
  21. doi request reprint Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction
    James R Harkness
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 159:55-62. 2010
    ..We sought to determine whether STRes provides incremental risk stratification to the TIMI risk score...
  22. ncbi request reprint Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PR
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA, USA
    Am Heart J 152:756-61. 2006
    ..A variety of imaging modalities have implicated impaired myocardial perfusion in the pathogenesis of acute coronary syndromes (ACSs)...
  23. ncbi request reprint Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial
    David A Morrow
    TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, Mass 02115, USA
    JAMA 297:1775-83. 2007
    ..Ranolazine is a novel antianginal agent that reduces ischemia in patients with chronic angina but has not been studied in patients with acute coronary syndromes (ACS)...
  24. doi request reprint Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi
    David A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 119:2758-64. 2009
    ..This effect must be balanced against an increased bleeding risk. We aimed to characterize the effect of prasugrel with respect to the type, size, and timing of MI using the universal classification of MI...
  25. ncbi request reprint Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial)
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Cardiol 99:344-8. 2007
    ..This finding supports the physiologic relevance of procedural MI and the continued effort to define therapies that decrease the risk of this complication...
  26. doi request reprint Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial
    Sean R Wilson
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 53:1510-6. 2009
    ..We aimed to evaluate the efficacy and safety of ranolazine in a larger and more diverse group of patients with angina than previously studied...
  27. doi request reprint Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36)
    Jessica L Mega
    Brigham and Women s Hospital, 350 Longwood Ave, 1st Floor, Boston, MA 02115, USA
    Circulation 121:1809-17. 2010
    ..In prior studies, sex-based treatment differences have been observed with the antiischemic ranolazine, with a possibly diminished effect in women...
  28. ncbi request reprint Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 151:1186.e1-9. 2006
    ..Ranolazine is a novel agent that inhibits the late sodium current thereby reducing cellular sodium and calcium overload and has been shown to reduce ischemia in patients with chronic stable angina...
  29. pmc Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLAR
    Matthew W Sherwood
    TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 159:964-971.e1. 2010
    ..The incremental prognostic use of the initial magnitude of troponin elevation and its value in conjunction with ST-segment resolution (STRes) in ST elevation myocardial infarction (STEMI) is less well defined...
  30. ncbi request reprint Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115
    Circulation 111:1217-24. 2005
    ..Whether the disparate outcomes exist independently of potential biases in treatment patterns remains unclear...
  31. ncbi request reprint Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry
    Benjamin M Scirica
    TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Cardiol 90:303-5. 2002
  32. doi request reprint Vorapaxar in the secondary prevention of atherothrombotic events
    David A Morrow
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 366:1404-13. 2012
    ..Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1...
  33. ncbi request reprint Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification
    Benjamin M Scirica
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Cardiol 90:821-6. 2002
    ..Given their high risk for adverse events, patients with secondary UAP should be treated aggressively...
  34. doi request reprint B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thr
    David A Morrow
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 55:1189-96. 2010
    ..We designed a prospective evaluation of the interaction between B-type natriuretic peptide (BNP) and the effect of ranolazine in patients with acute coronary syndromes (ACS) as part of a randomized, blinded, placebo-controlled trial...
  35. doi request reprint Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, and Harvard Medical School, Boston, USA
    N Engl J Med 369:1317-26. 2013
    ..The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear...
  36. doi request reprint Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomi
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, USA
    Lancet 371:1353-63. 2008
    ..We assessed the rate, outcomes, and prevention of ischaemic events in patients treated with prasugrel or clopidogrel with stents in the TRITON-TIMI 38 study...
  37. doi request reprint Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial
    Payal Kohli
    TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Clin Chem 58:257-66. 2012
    ..We investigated the prognostic performance of ST2 with respect to cardiovascular death (CVD) and heart failure (HF) in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) in a large multinational trial...
  38. doi request reprint Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 119:2032-9. 2009
    ..We designed a prospective evaluation of the effect of ranolazine on hyperglycemia as part of a randomized, double-blind, placebo-controlled outcomes trial...
  39. ncbi request reprint Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 50:1844-51. 2007
    ..Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, with clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)...
  40. doi request reprint Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial
    Jacob A Udell
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Chem 59:959-67. 2013
    ..We aimed to determine if early, more complete renin-angiotensin-aldosterone system inhibition (RAASI) in post-ACS patients without ventricular dysfunction or heart failure would result in a graded reduction in aldosterone concentrations...
  41. doi request reprint Efficacy and safety of vorapaxar in patients with prior ischemic stroke
    David A Morrow
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Stroke 44:691-8. 2013
    ..We tested the efficacy and safety of vorapaxar in a prespecified analysis in the stroke subcohort from a multinational, randomized, placebo-controlled trial...
  42. doi request reprint Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 127:1522-9, 1529e1-6. 2013
    ..Patients with peripheral artery disease are at risk of systemic atherothrombotic events, as well as acute and chronic limb ischemia and the need for peripheral revascularization...
  43. doi request reprint Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 158:335-341.e3. 2009
    ..Because SCH 530348 does not interfere with other pathways for hemostasis, it is possible that SCH 530348 reduces thrombosis with less increase in bleeding than do other potent antiplatelet agents...
  44. ncbi request reprint Troponins in acute coronary syndromes
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Prog Cardiovasc Dis 47:177-88. 2004
    ..Future generations of troponin assays may detect specific posttranslational modifications of troponins that may increase the analytic sensitivity for myocardial damage and offer insight into the timing and mechanism of myocardial injury...
  45. doi request reprint Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--G
    Mitul B Kadakia
    TIMI Study Group, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    JACC Cardiovasc Interv 3:1166-77. 2010
    ..The aim of this study was to evaluate anticoagulant use patterns and bleeding risk in a contemporary population of patients with acute coronary syndrome...
  46. doi request reprint Prognostic evaluation of catalytic iron in patients with acute coronary syndromes
    Dylan L Steen
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Cardiol 36:139-45. 2013
    ..Circulating catalytic iron ("free" iron) is that which is not bound to transferrin or ferritin and is available to generate reactive oxygen species that may have deleterious vascular effects...
  47. doi request reprint Myocardial ischemia and ventricular tachycardia on continuous electrocardiographic monitoring and risk of cardiovascular outcomes after non-ST-segment elevation acute coronary syndrome (from the MERLIN-TIMI 36 Trial)
    James R Harkness
    TIMI Study Group, Boston, Massachusetts, USA
    Am J Cardiol 108:1373-81. 2011
    ....
  48. doi request reprint Risk of heart failure complication during hospitalization for acute myocardial infarction in a contemporary population: insights from the National Cardiovascular Data ACTION Registry
    Ravi V Shah
    Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Circ Heart Fail 5:693-702. 2012
    ..Patients with acute myocardial infarction (MI) complicated by heart failure (HF) are subject to higher mortality during the index hospitalization. Early risk prediction and intervention may help prevent HF-related morbidity and mortality...
  49. ncbi request reprint Troponins in acute coronary syndromes
    Benjamin M Scirica
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Semin Vasc Med 3:363-74. 2003
    ....
  50. doi request reprint Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus
    Jacob A Udell
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Clin Cardiol 35:722-9. 2012
    ..In this review, we provide recommendations for the use of statins and aspirin for the prevention of cardiovascular events in high-risk patients with diabetes mellitus...
  51. doi request reprint Timing and duration of myocardial ischemia on Holter monitoring following percutaneous coronary intervention and their association with clinical outcomes (a PROTECT-TIMI 30 Substudy Analysis)
    C Michael Gibson
    TIMI Study Group, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Am J Cardiol 104:36-40. 2009
    ..Holter monitoring may be a useful surrogate end point in clinical trials...
  52. doi request reprint Relation of death within 90 days of non-ST-elevation acute coronary syndromes to variability in electrocardiographic morphology
    Zeeshan Syed
    Harvard MIT Division of Health Sciences and Technology, Cambridge, MA, USA
    Am J Cardiol 103:307-11. 2009
    ..In conclusion, our results suggest that increased variation in the entire heart beat morphology is associated with a considerably elevated risk of death and may provide information complementary to the analysis of heart rate...
  53. doi request reprint Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 306:2221-8. 2011
    ..Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel...
  54. doi request reprint Clopidogrel with or without omeprazole in coronary artery disease
    Deepak L Bhatt
    Veterans AffairsBoston Healthcare System, Brigham and Women s Hospital, Boston, MA 02132, USA
    N Engl J Med 363:1909-17. 2010
    ..Recently, concerns have been raised about the potential for PPIs to blunt the efficacy of clopidogrel...
  55. ncbi request reprint Chronic angina: definition, prevalence, and implications for quality of life
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Rev Cardiovasc Med 10:S3-10. 2009
    ..After a year of follow-up, though, much of the treatment differences are lost and all strategies (surgical/percutaneous revascularization or medical therapy) result in a significant improvement of angina symptoms...
  56. doi request reprint The clinical significance of continuous ECG (ambulatory ECG or Holter) monitoring of the ST-segment to evaluate ischemia: a review
    Neil J Wimmer
    Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Prog Cardiovasc Dis 56:195-202. 2013
    ..Future research is warranted to study the effects of newer medical agents or the selected use of revascularization in those patients with persistent silent ischemia despite current medical regiments. ..
  57. doi request reprint Established and novel biomarkers in ST-elevation myocardial infarction
    Jonathan W Waks
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Future Cardiol 7:523-46. 2011
    ....
  58. ncbi request reprint Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Circulation 113:2128-34; discussion 2151. 2006
  59. doi request reprint Implementation of a Hospital-wide Protocol for Induced Hypothermia Following Successfully Resuscitated Cardiac Arrest
    Paul M Szumita
    Department of Pharmacy, Brigham and Women s Hospital, Boston, MA, USA
    Crit Pathw Cardiol 9:216-20. 2010
    ..We describe our institutional guidelines for the initiation and management of induced hypothermia in patients successfully resuscitated from a cardiac arrest...
  60. pmc Evaluation of a clinical pathway for sedation and analgesia of mechanically ventilated patients in a cardiac intensive care unit (CICU): The Brigham and Women's Hospital Levine CICU sedation pathways
    Aaron W Aday
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, USA
    Eur Heart J Acute Cardiovasc Care 2:299-305. 2013
    ..We tested a clinical pathway for the use of sedation and analgesia during MV in a cardiac intensive care unit (CICU)...